Another older, small study of 32 older adults found that MK-677 boosted levels of growth hormone in participants to a level ...
FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
The FDA has approved a once-weekly therapy to improve growth for children aged 2 years and older with achondroplasia, according to an industry press release.Navepegritide (Yuviwel, Ascendis Pharma), a ...
Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results